All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Originally posted by @drjonesdc on TikTok · 63s|Watch on TikTok
Full video transcriptClick to expand

Auto-generated transcript of @drjonesdc's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.

  1. 0:00If you're on any of these guys right here, any of these medications,
  2. 0:03oz epic wagovimonjaro, these side effects might shock you.
  3. 0:07The nausea, the constipation, the muscle mass loss.
  4. 0:09Here's how you can stop it before it derails your progress.
  5. 0:12Even due to my channel, hi, I'm Dr. Jones DC, I'm weight loss expert.
  6. 0:15And what I'm about to tell you could save you from an unplanned pregnancy, for real.
  7. 0:19Ain't nobody got time for that.
  8. 0:20These medications slow your digestion so much that your birth control might even not absorb proper.
  9. 0:25We've already seen dozens of surprise pregnancies, so think about it.
  10. 0:28The pill goes through your system too fast and it can't do its job.
  11. 0:31So if you're on the pill and you're on these shots, then you need a backup plan.
  12. 0:36Like you need backup protection period.
  13. 0:37Using condoms or switching to an IUD or an implant might be something to consider.
  14. 0:41But for those other side effects, digestive enzymes for bloating, protein,
  15. 0:44even when you're not hungry, checking your P because when it's really dark,
  16. 0:48that means you're dehydrated.
  17. 0:49These medications work, there's no doubt.
  18. 0:50But part of the process is understanding these side effects and responding appropriately.
  19. 0:55So don't let a preventable side effect derail your transformation.
  20. 0:58And if you guys need some help with any of this, click on the link in the bio for crying out loud
  21. 1:01because this is, we're here to help.

@drjonesdc's Mounjaro side effects video, fact-checked

Lasting Weight Loss

TikTok creator

217.6K viewsWatch on TikTok

Quick answer

Tirzepatide and semaglutide delay gastric emptying, which raises a pharmacokinetically plausible concern about reduced oral contraceptive absorption, a concern acknowledged in tirzepatide's FDA prescribing information with specific guidance to use non-oral or barrier contraception for four weeks after initiation and dose escalation. However, no published clinical trial has confirmed elevated rates of oral contraceptive failure or unintended pregnancy among GLP-1 users, meaning the interaction remains mechanistically plausible but clinically unquantified. The muscle mass loss concern is better supported, with clinical data from the SURMOUNT and STEP trials confirming that lean mass loss accompanies fat loss during GLP-1 therapy, making protein optimization and resistance training relevant clinical considerations.

Video review standard

Clinical fact-check snapshot

FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.

GLP-1 social video fact-checksCompounded TirzepatideProvider discussion

Evidence signal

Source-backed review

Regulatory reality

Compounded Tirzepatide access requires the right clinical path

Safety screen

Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.

This page currently connects to 8 source-backed evidence items through visible references or structured citation data.

PubMed evidence trail

Research sources used to frame this page

For @drjonesdc's Mounjaro side effects video, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.

Provider decision path

Use local research to choose a safer review path

Direct answer

Compounded Tirzepatide is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.

Evidence check

Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.

Safety check

Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.

Next step

When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.

Claim path

Keep researching this tirzepatide video claims cluster

Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.

Page-specific review note

What this exact clip is really saying

This FormBlends review is specific to "@drjonesdc's Mounjaro side effects video, fact-checked" from Lasting Weight Loss. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tirzepatide and semaglutide delay gastric emptying, which raises a pharmacokinetically plausible concern about reduced oral contraceptive absorption, a concern acknowledged in tirzepatide's FDA prescribing information with specific guidance to use non-oral or barrier contraception for four weeks after initiation and dose escalation.

The reason this review is not generic is the source wording and the canonical claim label "glp1 mounjaro side effects no one talks about fyp glp1 foryoup." In this clip, the useful excerpt is: "If you're on any of these guys right here, any of these medications, oz epic wagovimonjaro, these side effects might shock you." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.

The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.

No published peer-reviewed study has confirmed that GLP-1 medications cause oral contraceptive failure at a clinically meaningful rate in real-world populations.
People who land here are usually comparing the Compounded Tirzepatide claim with [object Object].
The strongest next step is to compare the claim with FormBlends' Compounded Tirzepatide guide, evidence notes, and provider review path before acting.

Claim verdict

The useful answer behind this video

This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.

Claim being checked

Tirzepatide and semaglutide delay gastric emptying, which raises a pharmacokinetically plausible concern about reduced oral contraceptive absorption, a concern acknowledged in tirzepatide's FDA prescribing information with specific guidance to use non-oral or barrier contraception for four weeks after initiation and dose escalation.

FormBlends verdict

Compounded Tirzepatide safety, access, evidence, and fit

Evidence strength

Source-backed review with clinical or regulatory citations.

Patient-safe next step

Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.

What to do with this video

Use the clip as a claim to verify, not a treatment plan

What it helps with

  • Tirzepatide and semaglutide delay gastric emptying, which raises a pharmacokinetically plausible concern about reduced oral contraceptive absorption, a concern acknowledged in tirzepatide's FDA prescribing information with specific guidance to use non-oral or barrier contraception for four weeks after initiation and dose escalation. However, no published clinical trial has confirmed elevated rates of oral contraceptive failure or unintended pregnancy among GLP-1 users, meaning the interaction remains mechanistically plausible but clinically unquantified. The muscle mass loss concern is better supported, with clinical data from the SURMOUNT and STEP trials confirming that lean mass loss accompanies fat loss during GLP-1 therapy, making protein optimization and resistance training relevant clinical considerations.
  • Tirzepatide's FDA prescribing information specifically recommends switching to non-oral contraception or using barrier methods for four weeks after starting Mounjaro and after each dose increase.
  • No published peer-reviewed study has confirmed that GLP-1 medications cause oral contraceptive failure at a clinically meaningful rate in real-world populations.

What it may miss

  • It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
  • Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
  • Social video captions rarely show the full evidence base behind a claim.

Best next step

Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.

Review Compounded Tirzepatide

What You'll Learn

  • Tirzepatide's FDA prescribing information specifically recommends switching to non-oral contraception or using barrier methods for four weeks after starting Mounjaro and after each dose increase.
  • No published peer-reviewed study has confirmed that GLP-1 medications cause oral contraceptive failure at a clinically meaningful rate in real-world populations.
  • GLP-1 drugs slow gastric emptying, they do not speed it up. The creator's explanation of the mechanism was pharmacologically backwards.
  • The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) confirmed that lean mass loss accompanies weight loss on tirzepatide, validating the muscle loss concern raised in the video.
  • Switching to an IUD or subdermal implant while on GLP-1 therapy is a reasonable precaution recommended by some reproductive endocrinologists, even without definitive trial data.
  • The creator is a doctor of chiropractic, not a physician or pharmacist. Reproductive drug interaction guidance should come from a licensed prescriber who knows your full medication history.
  • Urine color as a hydration marker is a basic but clinically recognized monitoring tool, consistent with standard patient education materials on dehydration.

Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.

What did @drjonesdc actually say?

A chiropractor with 217,000 views on this video warned that GLP-1 medications like tirzepatide and semaglutide slow digestion so much that oral contraceptives "might even not absorb proper," citing "dozens of surprise pregnancies." He recommended backup contraception, including condoms, IUDs, or implants. He also touched on muscle loss, dehydration, and bloating as side effects worth managing, and suggested digestive enzymes and protein intake as responses. The birth control claim was the centerpiece, and it is the one that deserves the most scrutiny.

Does the science back this up?

Partially, but the evidence is weaker than this video implies. The theoretical mechanism is real: GLP-1 receptor agonists delay gastric emptying, which could theoretically reduce peak plasma concentrations of orally administered drugs. A pharmacokinetic study by Flint et al. (2013, Clinical Pharmacokinetics) showed liraglutide delayed gastric emptying and modestly reduced acetaminophen absorption. However, the FDA label for Mounjaro (tirzepatide) does not list oral contraceptive failure as a confirmed clinical interaction, and no large-scale epidemiological study has confirmed elevated unintended pregnancy rates specifically among GLP-1 users on the pill. The "dozens of surprise pregnancies" claim is anecdotal and unverifiable. Semaglutide's prescribing information does note a potential interaction with oral medications, but manufacturers of combined oral contraceptives have not issued formal alerts specific to GLP-1 combinations. The concern is biologically plausible. Calling it proven is a stretch.

What did they get wrong (or right)?

Let's give credit where it is due. The general advice to use backup contraception while on GLP-1 medications is actually in line with cautious clinical practice. The American College of Obstetricians and Gynecologists has not issued a formal warning, but several reproductive endocrinologists have publicly recommended exactly what this creator suggests: switching to non-oral methods like IUDs or implants if you are on a GLP-1 drug. That part is reasonable.

What is not reasonable is the framing. Saying "we've already seen dozens of surprise pregnancies" implies clinical data or a published case series. It does not exist in peer-reviewed literature as of this writing. That is irresponsible language from someone with a quarter million views. The mechanism he describes, where "the pill goes through your system too fast," is also backwards. GLP-1 drugs slow gastric emptying, meaning pills move more slowly, not faster. The absorption problem, if real, is about altered peak concentrations, not accelerated transit. Getting the pharmacology wrong while making a reproductive health claim is a significant error.

The muscle mass loss mention is accurate and well-documented. Wilding et al. (2021, New England Journal of Medicine) noted that a meaningful portion of weight lost on semaglutide included lean mass. Protein intake is a legitimate mitigation strategy supported by clinical guidance from obesity medicine specialists.

What should you actually know?

If you are on an oral contraceptive and a GLP-1 medication, the practical advice to use backup protection is defensible, even if the evidence base is not as solid as this video implies. But your prescribing physician, not a chiropractor's TikTok, should be making that call. Here is what the actual data supports:

  • GLP-1 receptor agonists do delay gastric emptying, which is a documented pharmacological effect confirmed across multiple trials.
  • The clinical significance of this delay for oral contraceptive efficacy has not been established in randomized controlled trials as of 2024.
  • Tirzepatide's FDA label advises patients on oral contraceptives to switch to a non-oral method or use barrier contraception for four weeks after starting therapy and after each dose escalation.
  • Muscle loss during GLP-1 therapy is real. Resistance training and adequate protein intake are the evidence-backed responses, not supplements sold through bio links.
  • Dehydration monitoring via urine color is a basic but clinically reasonable tip. GLP-1-induced nausea and reduced fluid intake can contribute to dehydration.

One more thing worth naming directly: the creator is a DC, a doctor of chiropractic, not an MD, DO, or pharmacist. That does not make everything he says wrong, but it is relevant context when he is discussing drug-drug interactions and reproductive medicine. Credentials matter when the stakes are a pregnancy.

Interested in GLP-1 or peptide therapy?

Get matched with licensed-provider review to help decide if it is right for you.

Free Assessment

About the Creator

Lasting Weight Loss · TikTok creator

217.6K views on this video

Mounjaro Side Effects No One Talks About #fyp #glp1 #foryoupagе #glp1medication #tirzepatide

Frequently asked questions

Quick answers based on this video and our medical team review.

What does the video say about tirzepatide's fda prescribing information specifically recommends switching to non-oral contraception?

Tirzepatide's FDA prescribing information specifically recommends switching to non-oral contraception or using barrier methods for four weeks after starting Mounjaro and after each dose increase.

What does the video say about no published peer-reviewed study has confirmed?

No published peer-reviewed study has confirmed that GLP-1 medications cause oral contraceptive failure at a clinically meaningful rate in real-world populations.

What does the video say about glp-1 drugs slow gastric emptying, they do not speed it?

GLP-1 drugs slow gastric emptying, they do not speed it up. The creator's explanation of the mechanism was pharmacologically backwards.

What does the video say about the surmount-1 trial (jastreboff et al., 2022, nejm) confirmed?

The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) confirmed that lean mass loss accompanies weight loss on tirzepatide, validating the muscle loss concern raised in the video.

What does the video say about switching to an iud?

Switching to an IUD or subdermal implant while on GLP-1 therapy is a reasonable precaution recommended by some reproductive endocrinologists, even without definitive trial data.

What does the video say about the creator?

The creator is a doctor of chiropractic, not a physician or pharmacist. Reproductive drug interaction guidance should come from a licensed prescriber who knows your full medication history.

Sources & references

Citations extracted from our medical team's review. Click any citation to search PubMed.

Educational use only. This fact-check is editorial content for general information. Nothing here is medical advice. Talk to a licensed provider about your specific situation before starting, stopping, or changing any supplement, peptide, or medication regimen.

Read More on This Topic

Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.

Not medical advice. This video was made by Lasting Weight Loss, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.